CD19 and neoplasm: However, the tumors in the mice treated with blinatumomab recurred rapidly due to the emergence of CD19-KO tumor variants, whereas the tumors were controlled in the mice that received TriBAFF/CD3/ABDCon until day 24 (Fig. 6B and 6C).